Common questions about Elica (FAQ)
Q: How quickly does Elica start working?
Studies used in the regulatory assessment of Elica focus on short time frames to measure initial changes. For conditions like atopic dermatitis (eczema) and psoriasis, research has typically observed symptomatic changes over defined periods of two to four weeks to contribute to the body of evidence regarding symptomatic change.
Q: Can Elica be used on the face?
Official drug documents describe restrictions for use on sensitive areas, including the face. This restriction is noted because the skin on the face is thinner and may be more susceptible to local side effects from potent topical corticosteroids.
Q: Is it true that Elica should not be stopped suddenly?
Regulatory documents acknowledge the risk of Topical Steroid Withdrawal (TSW) reactions, especially following prolonged or inappropriate use of high-potency topical steroids. If the medicine has been used over a long period, gradual discontinuation, rather than sudden stopping, may be a consideration to help avoid potential rebound effects.
Q: Are there different strengths of Elica available?
The active ingredient in Elica, Mometasone Furoate, is commonly available as a 0.1% concentration. This strength is supplied in various forms, such as a cream, an ointment, or a lotion, which are used depending on the treated area and skin condition.
Q: What kind of relief can be generally expected from using Elica?
Elica is indicated, according to official regulatory documents, for providing relief of the inflammatory and pruritic manifestations of certain skin conditions. This means it is officially described for use in connection with signs like redness, itching, and swelling associated with those conditions.
Q: Is Elica safe to use during pregnancy according to official sources?
Official product information, based on animal studies, indicates that Elica should be used during pregnancy only if the potential benefit is considered to outweigh the potential risk to the fetus. The decision to use Elica during pregnancy is subject to medical oversight.
Q: What is known about Elica use while breastfeeding?
It is unknown whether Mometasone Furoate, the active ingredient, is passed into human milk. Regulatory guidance states that a decision must be made to either discontinue nursing or discontinue the drug, taking into account the drug's importance to the nursing mother.
Q: Can Elica affect blood sugar levels?
Yes, regulatory warnings note that systemic absorption of topical corticosteroids carries a potential risk. This absorption can lead to manifestations such as hyperglycemia (high blood sugar) and glucosuria (sugar in the urine) in some patients while undergoing treatment.
Q: Is Elica known to cause any withdrawal symptoms when stopped?
Official documents recognize the risk of Topical Steroid Withdrawal (TSW) reactions following cessation. These reactions may include symptoms like intense redness, stinging, and burning that can occur after stopping prolonged or inappropriate use.
Q: Do official documents mention any known interactions with herbal supplements?
Official regulatory interaction sections primarily list interactions with specific medicines and enzyme inhibitors like CYP3A4. They do not typically document formal contraindications or interactions specifically for every single herbal supplement.
Q: Is Elica effective for dandruff or scalp psoriasis?
Elica is indicated for corticosteroid-responsive dermatoses. Some formulations, such as the lotion, are often used for conditions affecting the scalp, but specific efficacy claims for common dandruff are not universally stated in primary regulatory labels for all formulations.
Q: Can Elica make the treated area more sensitive to sunlight?
Official patient leaflets and warnings do not generally list photosensitivity (increased sun sensitivity) as a common or frequent side effect for Mometasone Furoate topical.
Q: Is Elica cream greasy or easily absorbed?
The official descriptions of the formulations note that the cream is generally a smooth, white to off-white consistency. It is generally considered less greasy and occlusive than the ointment formulation, which is generally associated with easier absorption into the skin compared to the ointment.
Q: Is it normal to feel a slight burning sensation when first applying Elica?
Burning and stinging are listed among the most frequently observed adverse reactions reported in clinical trials. This indicates that a slight burning or stinging feeling is a commonly reported initial experience.
Q: Do official patient leaflets warn about discoloration of skin?
Official adverse reaction lists for the product include the potential for hypopigmentation (lightening of skin color) and, less commonly, hyperpigmentation (darkening of skin color) as possible effects.
Q: Is Elica considered a high-potency topical corticosteroid?
Mometasone Furoate 0.1% in its various formulations is generally classified as a potent or intermediate-to-high potency topical corticosteroid, depending on the specific international classification system being used.
Q: Are there documented cases of Elica losing effectiveness over time?
Some regulatory documents acknowledge the potential for tachyphylaxis, which is the term for a rapidly developing, reduced response to the medicine's effects that can occur with continuous application of topical corticosteroids.
Q: What is the storage advice for Elica cream?
Elica is generally advised to be stored at a controlled room temperature, typically around 25 C (77 F). To maintain its stability and effectiveness, patients are often advised not to freeze or refrigerate the product.
Q: Are there specific ingredients in Elica that cause allergic reactions?
The official Summary of Product Characteristics (SmPC) lists all non-active ingredients, or excipients. Warnings may specifically mention excipients such as Propylene glycol or Butylhydroxytoluene that have the potential to cause local skin reactions.
